InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | 2026-05-22 | Marshall Richard Peter | Director | Purchase | 12.2K | $1.65 | $20K | 12.2K | View ↗ | |
| 2026-03-23 | 2026-03-24 | Moreadith Randall | Chief Scientific Officer | Sale | 6,500 | $2.86 | $19K | 0 | View ↗ | |
| 2026-03-19 | 2026-03-20 | Moreadith Randall | Chief Scientific Officer | Sale | 39.0K | $2.50 | $98K | 0 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenues | $130K+132.1% | $56K-13.8% | $65K+91.2% | $34K |
| Research and development | $13.2M+75.9% | $7.5M+213.2% | $2.4M+133.0% | $1.0M |
| General and administrative | $11.0M+14.3% | $9.6M+147.1% | $3.9M-34.8% | $6.0M |
| Total operating expenses | $24.2M+41.2% | $17.1M+172.3% | $6.3M-10.2% | $7.0M |
| Loss from operations | -$24.0M-40.9% | -$17.0M-444.8% | -$3.1M+55.1% | -$7.0M |
| Interest expense | -$213K+59.5% | -$526K+5.7% | -$558K | — |
| Change in fair value of convertible promissory notes | $0+100.0% | -$7.0M-231.0% | $5.4M | — |
| Change in fair value of warrants liabilities | $4.3M-67.6% | $13.2M+1121.5% | $1.1M+578.7% | -$225K |
| Gain on warrants expiration | $724K | $0 | — | — |
| Other income, net | $51K-77.6% | $228K-19.4% | $283K+2076.9% | $13K |
| Total other income, net | $4.8M-17.4% | $5.8M-30.4% | $8.4M+336.8% | -$3.5M |
| Loss before income taxes | -$19.2M-71.3% | -$11.2M | — | — |
| Provision for income taxes | -$18K | $0 | — | — |
| Net loss | -$19.2M-71.5% | -$11.2M-312.7% | $5.3M+150.1% | -$10.5M |
| Net loss attributable to noncontrolling interest | $33K-50.0% | $66K | $0-100.0% | $60K |
| NET LOSS ATTRIBUTABLE TO SERINA | -$19.2M-72.2% | -$11.1M-311.4% | $5.3M+150.4% | -$10.5M |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, BASIC | -$19.4M-74.5% | -$11.1M | — | — |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, DILUTED | -$19.4M-74.5% | -$11.1M | — | — |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, BASIC (in usd per share) | -$2K-26.5% | -$2K-164.0% | $2K+124.3% | -$10K |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, DILUTED (in usd per share) | -$2K-26.5% | -$2K-306.8% | $730+107.5% | -$10K |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC (in shares) | $10.2M+38.5% | $7.4M+229.3% | $2.2M+107.1% | $1.1M |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, DILUTED (in shares) | $10.2M+38.5% | $7.4M+0.1% | $7.4M+581.3% | $1.1M |
| Grant revenues | ||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Serina Therapeutics wins NYSE approval; 2027 listing compliance deadline set